The common approach towards symptoms is either ignoring it or panicking too much but neither is recommended. The best response is to get aware of the warning signs before taking Epcoritamab (Epkinly) therapy and be alert and inform the doctor when you notice any new signs after infusion. So here’s presenting the four warning signs of Epcoritamab that you shouldn’t miss.
Information about Epcoritamab injection in India, including its availability and appropriate access, can help patients and caregivers better understand their options.
1. Cytokine Release Syndrome (CRS)
Epcoritamab can cause CRS, including serious or life-threatening reactions. The signs and symptoms of CRS include pyrexia, hypotension, hypoxia, dyspnea, chills, and tachycardia. Concurrent neurological adverse reactions associated with CRS occurred in 2.5% of patients and included headache, confusional state, tremors, dizziness, and ataxia.
Follow a step-up dosing scheduling of Epcoritamab. Administer pretreatment medications to reduce the risk of CRS and monitor patients for potential CRS following Epcoritamab accordingly. Patients should be hospitalized for 24 hours after the administration of the first 48 mg dose. At the first signs or symptoms of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care as appropriate. Withhold or discontinue the therapy based on the severity of CRS
Patients who experience CRS (or other adverse reactions that impair consciousness) should be evaluated and advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution.
2. Immune Effector Cell-Associated Neurotoxicity Syndrome
Patients taking Epcoritamab may expect life-threatening and fatal immune effector cell-associated neurotoxicity syndrome (ICANS). Clinical manifestations of ICANS such as confusional state, lethargy, tremor, dysgraphia, aphasia, and non-convulsive status epilepticus can occur but symptoms are not limited to the mentioned ones. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for potential ICANS after Epcoritamab infusion. At the first signs or symptoms of ICANS, immediately evaluate patients and provide supportive therapy based on severity. Withhold or discontinue Epcoritamab per recommendations and consider further management per current practice guidelines.
Patients who experience signs or symptoms of ICANS or any other adverse reactions that impair cognition or consciousness should be evaluated, including potential neurology evaluation, and patients at increased risk should be advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution.
3. Infections
Monitor patients for signs and symptoms of infection prior to and during treatment with Epcoritamab therapy and treat appropriately. Do not administer Epcoritamab in patients experiencing active infections. Provide PJP prophylaxis prior to initiating treatment with Epcoritamab; consider initiating prophylaxis against herpes virus prior to starting Epcoritamab.
You can either withhold or discontinue the therapy permanently based on severity.
For patients prescribed Epkinly, questions about Buy Epkinly online in India should be discussed with the treating healthcare professional to ensure appropriate sourcing.
4. Cytopenias
Serious or severe cytopenias, including neutropenia, anemia, and thrombocytopenia can occur following Epcoritamab therapy.
Monitor complete blood counts throughout treatment. Based on the severity of cytopenias, temporarily withhold or permanently discontinue Epcoritamab. Consider prophylactic granulocyte colony-stimulating factor administration as applicable.
Every patient is different so are the symptoms and the treatment plan. Don’t compare with other patients despite the same type of disease. Emotional stability alongside the treatment dosing is important for patients receiving Epcoritamab therapy. Your next insight is just a click away. Stay connected at 24/7QualityMeds for more interesting news on Epcoritamab.
